Yuen Wo Tsang
Chief Tech/Sci/R&D Officer chez WAI YUEN TONG MEDICINE HOLDINGS LIMITED
Profil
Yuen Wo Tsang is currently the Director-Technical at Wai Yuen Tong Medicine Holdings Ltd.
and also holds the position of Technical Director at Luxembourg Institute of Health.
Dr. Tsang has a graduate degree from The University of Sydney and an undergraduate degree from the University of Aston.
Postes actifs de Yuen Wo Tsang
| Sociétés | Poste | Début |
|---|---|---|
| WAI YUEN TONG MEDICINE HOLDINGS LIMITED | Chief Tech/Sci/R&D Officer | 01/09/2018 |
Luxembourg Institute of Health
 Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass. | Chief Tech/Sci/R&D Officer | - |
Formation de Yuen Wo Tsang
| The University of Sydney | Graduate Degree |
| University of Aston | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WAI YUEN TONG MEDICINE HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
Luxembourg Institute of Health
Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass. | Commercial Services |
